ArticleWorld journal of urology2026
Diagnostic and treatment delays in penile cancer: a call to improve awareness and referral.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn men with penile cancer (PeCa), timely referral is crucial for optimizing clinical outcomes. We investigated the association between time from initial presentation to first surgical treatment and its effect on patient outcomes. MATERIALS AND
methodsData from a single center prospectively maintained database of patients with PeCa who underwent primary surgery between 2010 and 2024 were retrospectively analyzed, excluding those treated elsewhere. We assessed time intervals from initial disease appearance to referral across general practitioners (GP), urology or dermatology specialists (SP), and our center. We also compared disease characteristics, surgical approach, and oncological outcomes [i.e., overall survival and recurrence free survival (RFS)] among patients referred before or after 12 months from disease appearance.
resultsOverall, 48 patients were included. Median (IQR) time from presentation to our center was 12.4 (6.8–25.4) months. Referral pathways included: 13 (27%) patients were referred through GP, SP and our center [median time to treatment 13.9 (9.7–20.4) months], 8 (17%) were directly referred by the GP to our center [18.2 (9.1–26) months], 10 (21%) saw the SP first and were then referred to our center [6.8 (6.1–10.5) months], and 17 (36%) went directly to our center [14.3 (11-24.8) months]. Overall, 28 (58.3%) (Group 1) and 20 (41.7%) (Group 2) patients were surgically treated before or after 12 months of disease presentation, respectively. In Group 1, pT stage (P < 0.01), lymphovascular invasion (P < 0.01) and recurrence (P = 0.02) were significantly lower. Surgery after 12 months was associated with higher risk of recurrence [OR 4.6 (95% CI 1.29–18.2), P = 0.02] and lower 2-year RFS (33.8% [14.6–78.2] vs. 84% [68.8–100], P = 0.006).
conclusionEven in a high-income country, the median time from the initial presentation of PeCa to a tertiary center is alarmingly prolonged. This delay is associated to more advanced disease at treatment and potentially worse oncological outcomes. Raising public awareness about PeCa and establishing streamlined, dedicated referral pathways should be prioritized as essential strategies.
Indexed as
Identifiers
41779237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.